Blog
RSS FeedPosted by Michael Wonder on 30 Mar 2022
Pfizer’s oral COVID-19 treatment arrives in New Zealand
31 March 2022 - The first shipment of Pfizer’s new oral antiviral treatment for COVID-19, Paxlovid, has arrived in New ...
Posted by Michael Wonder on 28 Mar 2022
Te Pāti Māori demand accountability from PHARMAC CE for lie about live saving Trikafta drug cost
28 March 2022 - Today Te Pāti Māori stand in solidarity with the cystic fibrosis community of Aotearoa New Zealand ...
Posted by Michael Wonder on 22 Mar 2022
Doctors break rules for prescribing safe-sex drug as PHARMAC considers change
22 March 2022 - Doctors flagrantly broke rules for prescribing a safe-sex drug during 2021 COVID-19 lockdowns. ...
Posted by Michael Wonder on 20 Mar 2022
ProCare supports PHARMAC’s proposal to widen access to the flu vaccine
18 March 2022 - Leading health care provider ProCare has today made a submission in support of PHARMAC’s proposal to ...
Posted by Michael Wonder on 18 Mar 2022
Advocates say PHARMAC too slow on drugs to help treat COVID-19
19 March 2022 - Kiwis have been left waiting for a new antiviral drug to treat COVID-19 because PHARMAC was too ...
Posted by Michael Wonder on 17 Mar 2022
PHARMAC widening access to rituximab and zoledronic acid
17 March 2022 - PHARMAC is widening access to two medicines, rituximab and zoledronic acid, estimated to benefit 1,750 New Zealanders ...
Posted by Michael Wonder on 16 Mar 2022
PHARMAC deal good news for New Zealanders
16 March 2022 - The Government is welcoming news the national drug-funding agency PHARMAC has secured an agreement for medicines ...
Posted by Michael Wonder on 16 Mar 2022
PHARMAC to fund new treatments for lung and ovarian cancer
16 March 2022 - PHARMAC has confirmed today they are funding a bundle deal which will give New Zealanders more ...
Posted by Michael Wonder on 11 Mar 2022
Diabetes NZ to kick-start campaign for PHARMAC funding for glucose monitors
11 March 2022 - Diabetes NZ wants PHARMAC to fund next-generation blood sugar monitors for people with the debilitating disease. ...
Posted by Michael Wonder on 10 Mar 2022
Ronapreve: first COVID-19 therapeutic drug to get Medsafe's approval not effective against Omicron
10 March 2022 - The first new COVID-19 therapeutic drug to get Medsafe's approval demonstrates "significantly diminished potency" against Omicron. ...
Posted by Michael Wonder on 10 Mar 2022
Thirty six medicines added to PHARMAC’s waiting list as New Zealand’s medicines crisis worsens
10 March 2022 - PHARMAC has just released its Options for Investment list, which includes 36 new medicines since it ...
Posted by Michael Wonder on 09 Mar 2022
Pūahoaho: clarity around PHARMACs priority lists
9 March 2022 - PHARMAC has released up to date information about its priority lists, including a list of ...
Posted by Michael Wonder on 07 Mar 2022
PHARMAC proposes widened access to the flu vaccine for Māori and Pacific peoples for 2022 season
8 March 2022 - PHARMAC is consulting on a proposal to widen access to the funded influenza vaccine to include Māori ...
Posted by Michael Wonder on 06 Mar 2022
The shortfalls of PHARMAC and why the public system simply can’t shoulder it alone
7 March 2022 - Rob Hennin, CEO of nib New Zealand discusses the shortfalls of the PHARMAC system when it ...
Posted by Michael Wonder on 04 Mar 2022
PHARMAC updates access criteria for remdesivir
4 March 2022 - PHARMAC has heard from our expert advisors and clinicians treating people with COVID-19 that we need to ...